ERBB2 and breast carcinoma: The NALA clinical trial, a Phase III study, was designed to compare two TKIs, neratinib vs. lapatinib, both in combination with capecitabine in patients with metastatic HER2-positive breast cancer who had received at least two prior anti-HER2-based regimens.